US 12,214,075 B2
Apixaban suspension and preparation method
Ioannis Psarrakis, Lavrion (GR); and Konstantinos Lioumis, Lavrion (GR)
Assigned to PHARMA-DATA RESEARCH AND DEVELOPMENT SINGLE MEMBER S.A., Lavrio (GR)
Appl. No. 18/703,824
Filed by PHARMA-DATA RESEARCH AND DEVELOPMENT SINGLE MEMBER S.A., Lavrio (GR)
PCT Filed Oct. 25, 2022, PCT No. PCT/EP2022/079839
§ 371(c)(1), (2) Date Apr. 23, 2024,
PCT Pub. No. WO2023/072967, PCT Pub. Date May 4, 2023.
Claims priority of provisional application 63/272,407, filed on Oct. 27, 2021.
Claims priority of application No. 2029536 (NL), filed on Oct. 27, 2021.
Prior Publication US 2024/0325306 A1, Oct. 3, 2024
Int. Cl. A61K 9/10 (2006.01); A61K 9/00 (2006.01); A61K 31/4545 (2006.01); A61K 47/12 (2006.01); A61K 47/36 (2006.01); A61K 47/46 (2006.01)
CPC A61K 9/10 (2013.01) [A61K 9/0095 (2013.01); A61K 31/4545 (2013.01); A61K 47/12 (2013.01); A61K 47/36 (2013.01); A61K 47/46 (2013.01)] 20 Claims
 
1. A buffered oral aqueous apixaban suspension comprising a buffering agent and 0.08-0.20 w/v % micronized apixaban having a pH of 1.5-6.5, the suspension being void of emulsifier and surfactant.